🔎 Trials Near Me

Beranda › Kanker Payudara › Kansas

Uji klinis Kanker Payudara di Kansas

26 studi untuk Kanker Payudara mencari peserta di lokasi di Kansas.

Kota di Kansas

Teks studi resmi (Bahasa Inggris)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Veteran Administration Eastern Kansas Healthcare, Leavenworth
  • dan 4 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

  • The University of Kansas Cancer Center, Westwood
Menerima pesertaFase 3
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06377852

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

  • Cancer Center of Kansas, Wichita
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06492616

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

  • University of Kansas Hospital-Cancer Center, Fairway
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07287917

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  • University of Kansas Cancer Center, Westwood
  • Cancer Center of Kansas, Wichita
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06982521

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • HaysMed, Hays
  • dan 10 lainnya
Menerima pesertaFase 3
Usia 18 hingga 60 · Wanita · Diperbarui 2 Sep 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • AMR Kansas City Oncology, Kansas City
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT06072612

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

  • Hays Medical Center Dreiling-Schmidt Cancer Institute, Hays
  • KCCC West, Kansas City
  • KCCC Overland Park, Overland Park
  • dan 3 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Semua usia · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT02302742

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Cancer Center-Overland Park, Overland Park
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06500481

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

  • University of Kansas Medical Center, Fairway
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06263543

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

  • University of Kansas Cancer Center, Kansas City
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 45 hingga 74 · Wanita · Diperbarui 4 Agu 2026 · NCT06195306

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • University of Kansas Medical Center (KUMC), Westwood
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT05579366

E-Mindfulness Approaches for Living After Breast Cancer

  • Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka
Menerima pesertaFase 3
Usia 18 hingga 50 · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT06748222

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

  • University of Kansas Cancer Center, Kansas City
Menerima pesertaFase 2
Usia 18 hingga 55 · Wanita · Diperbarui 27 Jul 2026 · NCT06184750

HER2-positive Breast Cancer Registry

  • The University of Kansas Cancer Center, Westwood
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jul 2026 · NCT06603597

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

  • University of Kansas Cancer Center, Kansas City
Menerima pesertaFase 2
Usia 35 ke atas · Wanita · Diperbarui 7 Jul 2026 · NCT05941520

Integrated Cancer Repository for Cancer Research

  • Saint Luke's Cancer Instititute - South, Overland Park
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

  • The University of Kansas Cancer Center, Westwood
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT06757634

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

  • The University of Kansas Cancer Center (KUCC), Fairway
  • The University of Kansas Cancer Center - Westwood, Kansas City
  • KUCC - Indian Creek, Overland Park
  • dan 3 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT07220135

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

  • University of Kansas Cancer Center, Kansas City
  • The University of Kansas Cancer Center - Olathe, Olathe
  • University of Kansas Cancer Center-Overland Park, Overland Park
  • dan 8 lainnya
Menerima pesertaFase 3
Usia 50 hingga 70 · Semua jenis kelamin · Diperbarui 23 Apr 2026 · NCT04852887

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

  • The University of Kansas Cancer Center, Westwood
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Apr 2026 · NCT06374459

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • dan 6 lainnya
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

  • University of Kansas Cancer Center, Westwood
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Jan 2026 · NCT06401421

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

  • Cancer Center of Kansas, Wichita
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Nov 2025 · NCT04553770

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

  • University of Kansas Medical Center, Kansas City
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 30 hingga 65 · Wanita · Diperbarui 29 Okt 2025 · NCT00291096

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

  • HaysMed University of Kansas Health System, Hays
  • University of Kansas Cancer Center-West, Kansas City
  • University of Kansas Cancer Center, Kansas City
  • dan 5 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT03418961

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.